IMPROVE-IT study (ezetimibe/simvastatine) continues
The IMPROVE-IT trial comparing ezetimibe/simvastatin to simvastatin alone for the prevention of cardiovascular events will continue, following a planned review by the study's data safety monitoring board (DSMB).
In 2010, the completion of the IMPROVE-IT trial was pushed back from 2012 to June 2013, while last year the DSMB recommended that the study continue unchanged. The trial includes 18 141 patients and its design calls for the collection of 5250 clinical endpoints.
Based on the targeted number of clinical endpoints and the rate at which events are being reported, the trial is projected to conclude in September 2014. The IMPROVE-IT Executive Committee and Merck will continue to monitor the progress of the study, and Merck will update the study timeline if appropriate. Merck remains blinded to the actual results of this analysis and to other IMPROVE-IT safety and efficacy data. No additional interim analyses are planned.
Merck news release